Should I buy or sell BioMarin Pharmaceutical stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks .

What is BioMarin Pharmaceutical's stock price target for 2024?

23 Wall Street analysts have issued 1-year target prices for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's share price to reach $112.65 in the next year. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts .

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN stock has decreased by 8.8% and is now trading at $94.40. View the best growth stocks for 2023 here .

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,080,000 shares, a decline of 6.4% from the October 31st total of 3,290,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is presently 2.0 days. View BioMarin Pharmaceutical's Short Interest .

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our BMRN earnings forecast .

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by $0.02. The biotechnology company had revenue of $581.33 million for the quarter, compared to analyst estimates of $603.51 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.45% and a net margin of 6.36%.

What ETFs hold BioMarin Pharmaceutical's stock?

ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Goldman Sachs Future Health Care Equity ETF (GDOC) , VanEck Biotech ETF (BBH) , BNY Mellon Innovators ETF (BKIV) , First Trust Innovation Leaders ETF (ILDR) and VictoryShares Nasdaq Next 50 ETF (QQQN) .

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $0.08-0.28 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $617-697 million, compared to the consensus revenue estimate of $652.66 million.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com . Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI) , (MDVN) (MDVN) , Incyte (INCY) , First Solar (FSLR) , United Airlines (UAL) , Dynavax Technologies (DVAX) , Micron Technology (MU) , Vertex Pharmaceuticals (VRTX) , (KITE) (KITE) and Freeport-McMoRan (FCX) .

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.77%), Barclays PLC (2.96%), Ameriprise Financial Inc. (2.74%), Fort Washington Investment Advisors Inc. OH (0.70%), Charles Schwab Investment Management Inc. (0.69%) and Northern Trust Corp (0.65%). Insiders that own company stock include Brian Mueller , Charles Greg Guyer , Dennis Slamon , George Eric Davis , Henry J Fuchs , Jean Jacques Bienaime , Jeffrey Robert Ajer , Mark J Alles , Michael G Grey , Richard A Meier and V Bryan Lawlis . View institutional ownership trends .

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$94.40

+1.98 (+2.14%)

(As of 12/4/2023 ET)

Compare

Today's Range: $92.27
▼
$94.97
50-Day Range: $76.22
▼
$94.40
52-Week Range: $76.02
▼
$117.77

Volume: 3.46 million shs
Average Volume: 1.40 million shs
Market Capitalization: $17.78 billion

P/E Ratio: 122.60
Dividend Yield: N/A
Price Target: $112.65

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.61 Rating Score
Upside/Downside: 19.3% Upside
$112.65 Price Target
Short Interest: Healthy
1.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.93
Upright™ Environmental Score
News Sentiment: 1.05
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 84.75%
From $1.18 to $2.18 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

75th out of 952 stocks

Pharmaceutical Preparations Industry

20th out of 434 stocks

3.3

Analyst's Opinion

Consensus Rating
BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 14 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $112.65, BioMarin Pharmaceutical has a forecasted upside of 19.3% from its current price of $94.40.
Amount of Analyst Coverage
BioMarin Pharmaceutical has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.64% of the outstanding shares of BioMarin Pharmaceutical have been sold short.
Short Interest Ratio / Days to Cover
BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioMarin Pharmaceutical has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BioMarin Pharmaceutical does not currently pay a dividend.
Dividend Growth
BioMarin Pharmaceutical does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.
Environmental Sustainability
The Environmental Impact score for BioMarin Pharmaceutical is -2.93.

3.9

News and Social Media Coverage

News Sentiment
BioMarin Pharmaceutical has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for BioMarin Pharmaceutical this week, compared to 5 articles on an average week.
Search Interest
16 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
MarketBeat Follows
7 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.
Percentage Held by Institutions
92.78% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for BioMarin Pharmaceutical are expected to grow by 84.75% in the coming year, from $1.18 to $2.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioMarin Pharmaceutical is 122.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 115.77.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioMarin Pharmaceutical is 122.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 114.67.
Price to Earnings Growth Ratio
BioMarin Pharmaceutical has a PEG Ratio of 1.44. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
BioMarin Pharmaceutical has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BMRN Stock News Headlines

December 1, 2023 | markets.businessinsider.com

Strategic Advancements and Long-Term Gains: Buy Rating on BioMarin Amidst Roctavian’s European Rollout

December 1, 2023 | finance.yahoo.com

Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 30, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Ascendis Pharma (ASND) and BioMarin Pharmaceutical (BMRN)

November 28, 2023 | finance.yahoo.com

BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany

November 28, 2023 | finance.yahoo.com

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

November 23, 2023 | finance.yahoo.com

BioMarin Pharmaceutical's (NASDAQ:BMRN) investors will be pleased with their 13% return over the last three years

November 15, 2023 | msn.com

Wells Fargo starts BioMarin at overweight, cites activist involvement

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 8, 2023 | markets.businessinsider.com

Oppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)

November 7, 2023 | bizjournals.com

Activist investor takes stake in BioMarin as drug maker switches out CEOs

November 7, 2023 | markets.businessinsider.com

Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change

November 7, 2023 | msn.com

Biggest stock movers today: BioMarin, Alteryx, Tripadvisor and more

November 7, 2023 | finance.yahoo.com

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake

November 7, 2023 | investorplace.com

BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals

November 7, 2023 | ca.finance.yahoo.com

Exclusive-Activist investor Elliott targets drugmaker BioMarin -sources

November 7, 2023 | seekingalpha.com

BioMarin: Keeping Bullish View After Q3 Earnings

November 2, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Theravance Biopharma (TBPH), BioMarin Pharmaceutical (BMRN)

November 2, 2023 | finance.yahoo.com

BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut

November 2, 2023 | finance.yahoo.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript

November 1, 2023 | bizjournals.com

Genentech CEO Alexander Hardy resigns effective immediately to replace Jean-Jacques Bienaimé as CEO at BioMarin

November 1, 2023 | finance.yahoo.com

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

November 1, 2023 | finance.yahoo.com

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

November 1, 2023 | finance.yahoo.com

Biomarin Pharmaceutical Inc (BMRN) Reports 15% Total Revenue Growth in Q3 2023

November 1, 2023 | finance.yahoo.com

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

November 1, 2023 | seekingalpha.com

BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation

October 27, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

See More Headlines

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BMRN
CUSIP: 09061G10
CIK: 1048477
Web: www.bmrn.com
Phone: (415) 506-6700
Fax: 415-382-7889
Employees: 3,082
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $112.65
High Stock Price Target: $185.00
Low Stock Price Target: $78.00
Potential Upside/Downside: +19.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.61
Research Coverage: 23 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.77
Trailing P/E Ratio: 122.60
Forward P/E Ratio: 80.00
P/E Growth: 1.44
Net Income: $141.56 million
Net Margins: 6.36%
Pretax Margin: 6.56%
Return on Equity: 4.45%
Return on Assets: 3.23%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 2.54
Quick Ratio: 1.65

Sales & Book Value

Annual Sales: $2.10 billion
Price / Sales: 8.48
Cash Flow: $1.50 per share
Price / Cash Flow: 62.73
Book Value: $24.82 per share
Price / Book: 3.80

Miscellaneous

Outstanding Shares: 188,370,000
Free Float: 184,902,000
Market Cap: $17.78 billion
Optionable: Optionable
Beta: 0.40

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Jean-Jacques Bienaime M.B.A. (Age 70)
Chairman & CEO
Comp: $3.52M
Mr. Brian R. Mueller (Age 49)
CFO & Executive VP
Comp: $1.15M
Mr. George Eric Davis (Age 52)
Executive VP, Chief Legal Officer, General Counsel & Secretary
Comp: $1.23M
Mr. Jeffrey Robert Ajer (Age 61)
Chief Commercial Officer
Comp: $1.18M
Dr. Henry J. Fuchs M.D. (Age 65)
Ph.D., President of Worldwide Research & Development
Comp: $1.49M
Ms. Erin Burkhart
Group VP & Chief Accounting Officer
Dr. Kevin Eggan Ph.D.
Chief Scientific Officer & Senior VP of Research and Early Development
Traci McCarty
Group Vice President of Investor Relations
Mr. Philip Lo Scalzo
Chief Compliance Officer
Ms. Marni Kottle
Chief Communications Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.
What is BioMarin Pharmaceutical's stock price target for 2024?: 23 Wall Street analysts have issued 1-year target prices for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's share price to reach $112.65 in the next year. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.
How have BMRN shares performed in 2023?: BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN stock has decreased by 8.8% and is now trading at $94.40.
View the best growth stocks for 2023 here.
Are investors shorting BioMarin Pharmaceutical?: BioMarin Pharmaceutical saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,080,000 shares, a decline of 6.4% from the October 31st total of 3,290,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is presently 2.0 days.
View BioMarin Pharmaceutical's Short Interest.
When is BioMarin Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BMRN earnings forecast.
How were BioMarin Pharmaceutical's earnings last quarter?: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by $0.02. The biotechnology company had revenue of $581.33 million for the quarter, compared to analyst estimates of $603.51 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.45% and a net margin of 6.36%.

What ETFs hold BioMarin Pharmaceutical's stock?: ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV), First Trust Innovation Leaders ETF (ILDR) and VictoryShares Nasdaq Next 50 ETF (QQQN).
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?: BioMarin Pharmaceutical issued an update on its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $0.08-0.28 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $617-697 million, compared to the consensus revenue estimate of $652.66 million.
What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?: 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.
What other stocks do shareholders of BioMarin Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).
Who are BioMarin Pharmaceutical's major shareholders?: BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.77%), Barclays PLC (2.96%), Ameriprise Financial Inc. (2.74%), Fort Washington Investment Advisors Inc. OH (0.70%), Charles Schwab Investment Management Inc. (0.69%) and Northern Trust Corp (0.65%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier and V Bryan Lawlis.
View institutional ownership trends.
How do I buy shares of BioMarin Pharmaceutical?: Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BMRN) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BMRN Stock Price History

BMRN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BMRN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™